August 2, 2012 / 11:28 AM / 5 years ago

Valeant reports loss on higher costs

Aug 2 (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International reported a second-quarter net loss on Thursday as operating costs and interest expenses outpaced higher product sales.

The net loss was $21.6 million, or 7 cents a share, compared with a profit of $56.4 million, or 17 cents a share, the year earlier.

Revenue rose 35 percent to $820.1 million.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below